GREM1 deficiency induced bone marrow adipose niche promotes B‐cell acute lymphoblastic leukemia disease progression
International Journal of Cancer · 2025
DOI: 10.1002/ijc.35418 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Lili Song und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Nutrition, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Intercellular Signaling Peptides and Proteins, Bone Marrow, Adipose Tissue, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shanghai Municipality, Shanghai Municipal Health Commission, National Key Research and Development Program of China.
Abstract (Originalsprache)
Relapse and disease progression are the primary causes of treatment failure and subsequent mortality in children with B‐cell acute lymphocytic leukemia (B‐ALL). At diagnosis and during treatment, dyslipidemia and the bone marrow adipose microenvironment are commonly observed in pediatric leukemia. However, the intricate connection between these factors and disease progression remains largely unexplored. We found that abnormal triglyceride accumulation increased the risk of death. Further investigation into the adipogenic potential of BM‐MSCs revealed a correlation between higher adipogenicity and elevated serum TG levels, which subsequently led to the rapid proliferation of leukemia cells and heightened the risk of post‐relapse mortality. Through RNA sequencing, Gremlin1 (GREM1) was identified as an important factor affecting adipogenicity. Silencing of GREM1 in BM‐MSCs induced adipogenic differentiation, partly through the BMP/SMAD signaling pathway. In an in vitro co‐culture model, shGREM1‐MSCs promoted B‐ALL cell proliferation and induced drug resistance to dexamethasone, while increasing sensitivity to L‐asparaginase. Furthermore, GREM1‐deficient BM‐MSCs promoted B‐ALL disease progression in xenograft models. This study provides new insights into overcoming drug resistance, relapse, and death by elucidating the novel mechanism by which GREM1 deficiency induces adipogenic differentiation of BM‐MSCs and promotes B‐ALL disease progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Nutrition, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Hematology & Oncology, Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Förderung
- Natural Science Foundation of Shanghai Municipality
- Shanghai Municipal Health Commission
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Song, L., Zhang, R., Pan, L., Mi, Q., Yang, Y., Wang, X., Ma, Y., Shen, S., Li, B., Li, Y., & Hong, L. (2025). GREM1 deficiency induced bone marrow adipose niche promotes B‐cell acute lymphoblastic leukemia disease progression. International Journal of Cancer. https://doi.org/10.1002/ijc.35418
Vancouver
Song L, Zhang R, Pan L, Mi Q, Yang Y, Wang X, et al. GREM1 deficiency induced bone marrow adipose niche promotes B‐cell acute lymphoblastic leukemia disease progression. International Journal of Cancer. 2025. doi:10.1002/ijc.35418
BibTeX
@article{Song2025,
author = {Song, Lili and Zhang, Rui and Pan, Liya and Mi, Qiang and Yang, Yi and Wang, Xiang and Ma, Yani and Shen, Shuhong and Li, Benshang and Li, Yanxin and Hong, Li},
title = {GREM1 deficiency induced bone marrow adipose niche promotes B‐cell acute lymphoblastic leukemia disease progression},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.35418}
}
EUVIMED